Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
April 2019
-
Media ReleaseEurope-Africa partnership spearheads development of next-generation antimalarial drugThe European & Developing Countries Clinical Trials Partnership (EDCTP) grants EUR 10 million over five years to "WANECAM 2" a unique collaboration between antimalarial drug researchers in…
-
Media ReleaseSandoz drives differentiated portfolio with deal to commercialize new treatment for Opioid-Induced Constipation in key European countriesAgreement with Shionogi to commercialize Rizmoic® (naldemedine) in Germany, UK and Netherlands, plus right of first refusal for certain other European markets Rizmoic® is an innovative medicine…
-
Media ReleaseNovartis continues transformation into a leading medicines company with completion of the Alcon spin-offNovartis positioned for sustained growth, including plans to improve Innovative Medicines core margins into mid-30s by 2022 Novartis has a catalyst-rich pipeline with 10 potential blockbuster…
-
Media ReleaseNovartis updates on the migraine collaboration with AmgenBasel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of…
-
Media ReleaseSandoz resubmits biosimilar pegfilgrastim application to US FDASandoz pursues US approval for biosimilar pegfilgrastim, a long-acting version of supportive oncology medicine filgrastim Pegfilgrastim is used to reduce the incidence of neutropenia, one…
-
Media ReleaseNovartis first-in-class Cosentyx® approved in China for psoriasis patientsChina Health Authority NMPA approved Cosentyx® (secukinumab) for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy Cosentyx is…
-
Media ReleaseAveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, ColoradoFacility to become the largest of four state-of-the-art sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy …
-
Media ReleaseNovartis adds clinical and preclinical anti-inflammatory programs to portfolio with acquisition of IFM TreAcquisition will give Novartis one clinical and two preclinical programs targeting the NLRP3 inflammasome, a key component of the innate immune system Selective inhibition of the NLRP3…
March 2019
-
Key ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active diseaseMayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1] Up to 80% of patients…
-
Key ReleaseNovartis plans for Alcon spin-off on April 9, 2019Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
-
Media ReleaseAlcon Announces Acquisition of PowerVision, Inc.Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
-
Media ReleaseNovartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathyStudy is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019…
Pagination
- ‹ Previous page
- 1
- …
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- …
- 100
- › Next page